This article is more than 5 years old. Information may no longer be current.

Eye Tech Care’s glaucoma treatment approved in China

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The China Food and Drug Administration has approved Eye Tech Care’s EyeOP1 glaucoma treatment product, according to a company press release.

EyeOP1 treats glaucoma with high-intensity focused ultrasound technology and is the first noninvasive medical device approved for glaucoma treatment in China, the release said.

The procedure takes less than 3 minutes and has a short learning curve.

“We are convinced that our technology will bring high value to the glaucoma market in China and provide new treatment options to patients,” Dietrich Wolf, PhD, Eye Tech Care CEO, said in the release. “Along with our shareholders from China and Europe, we believe that this is a great example of cross-border cooperation between France and China, and the beginning of a promising journey for our company. We are now switching gears to prepare for commercial launch in China.”